Although treatments can often seem standard and straightforward, the more we know about the patient, the better our chance of helping them to achieve successful outcomes.
The Ontario College of Pharmacists has announced it will take steps to address preferred provider networks—including exploring stronger regulatory responses.
Diltiazem used for ventricular rate control in patients with atrial fibrillation inhibits apixaban and rivaroxaban elimination, possibly causing overanticoagulation.